Search Results

You are looking at 81 - 90 of 375 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer Principal Investigator: Jasgit C. Sachdev, MD Condition: Triple negative breast

Full access

Presenter: Nadeem R. Abu-Rustum

as bevacizumab and pembrolizumab is difficult in this patient population, because bevacizumab and pembrolizumab are not widely available, are expensive, and require specific expertise to be delivered. Despite their improved activity over traditional

Full access

Amin Haiderali, Min Huang, Wilbur Pan, Grace Fox, Dylan Maciel, and Andrew Frederickson

nab-paclitaxel for PFS. Statistical superiority was also reported for pembrolizumab+paclitaxel compared to paclitaxel (for OS and PFS), paclitaxel+ bevacizumab (for OS) and ixabepilone+bevacizumab (for OS). Conclusions : These analyses suggest

Full access

Sonia Oskouei, Amy Graham Russell, Yolaine Jeune-Smith, and Ajeet Gajra

critical therapies with the potential to lower cost of care. There are 9 FDA approved therapeutic oncology biosimilars to 3 reference molecules: trastuzumab (5), bevacizumab (2) and rituximab (2), in addition to supportive care biosimilars for hematopoietic

Full access

Leora Horn

guidelines, maintenance therapy is an option for select patients with tumor response or stable disease and is not considered the standard of care for all patients. Category 1 options in continuation maintenance therapy include single-agent bevacizumab and

Full access

Bendamustine and Bevacizumab for Patients With Advanced Cancers Principal Investigator: Apostolia M. Tsimberidou, MD, PhD Condition: Advanced cancers Institution: The University of Texas MD Anderson Cancer Center, Houston, Texas Bendamustine is

Full access

Presenter: Dustin A. Deming

molecular features of the tumor. Across the continuum of treatment, patients usually received FOLFOX (5-FU/leucovorin/oxaliplatin) and/or FOLFIRI (5-FU/leucovorin/irinotecan) ± bevacizumab and an agent targeting the epidermal growth factor receptor (EGFR

Full access

Presenter: Deborah K. Armstrong

enrolled patients with newly diagnosed, stage III–IV, high-grade serous/endometrioid ovarian, fallopian tube, or primary peritoneal cancer. 2 All subjects had to have undergone ≥3 cycles of bevacizumab with their initial chemotherapy. At the end of

Full access

NCCN Breast Cancer Panel Reaffirms Current Position and Recommendation Regarding the Use of Bevacizumab in Metastatic Breast Cancer The Expert Breast Cancer Panel of the NCCN met July 10–12, 2011, in Philadelphia, Pennsylvania. The

Full access

Robert J. Morgan Jr, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Matthew A. Powell, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Julian C. Schink, Nelson Teng, Theresa L. Werner, Mary A. Dwyer, and Miranda Hughes

treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease (mainly epithelial ovarian cancer), and 6) management of drug/hypersensitivity reactions. 1